Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Total Non-Current Liabilities (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $60.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $60.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $60.8 million, a N/A change, with the full-year FY2024 number at $43.2 million, changed N/A from a year prior.
  • Total Non-Current Liabilities was $60.8 million for Q3 2025 at Orchestra BioMed Holdings, up from $42.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $60.8 million in Q3 2025 to a low of $5.3 million in Q1 2022.
  • A 4-year average of $37.9 million and a median of $40.9 million in 2022 define the central range for Total Non-Current Liabilities.
  • Biggest YoY gain for Total Non-Current Liabilities was 546.56% in 2023; the steepest drop was 546.56% in 2023.
  • Orchestra BioMed Holdings' Total Non-Current Liabilities stood at $40.9 million in 2022, then decreased by 11.02% to $36.4 million in 2023, then increased by 18.5% to $43.2 million in 2024, then surged by 40.87% to $60.8 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Total Non-Current Liabilities are $60.8 million (Q3 2025), $42.3 million (Q2 2025), and $42.1 million (Q1 2025).